title: Orlistat augments postprandial increases in glucagon-like peptide-1 in obese type 2 diabetic patients: response to Damci et al.
authors.forename: Michael
authors.initials: M
authors.lastname: Horowitz
authors.forename: Christine
authors.initials: C
authors.lastname: Feinle-Bisset
authors.forename: Karen
authors.initials: K
authors.lastname: Jones
authors.forename: Michael
authors.initials: M
authors.lastname: Nauck
mesh_terms: D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications; D005934:Glucagon / Q000097:blood*; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D009765:Obesity / Q000097:blood* / Q000150:complications; D000077403:Orlistat; D010446:Peptide Fragments / Q000097:blood*; D019518:Postprandial Period; D011498:Protein Precursors / Q000097:blood*
chemical_list: D019440:Anti-Obesity Agents; D007783:Lactones; D010446:Peptide Fragments; D011498:Protein Precursors; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000077403:Orlistat